Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: A touch sensing apparatus is provided comprising: a light transmissive panel that defines a touch surface, a plurality of light emitters and detectors arranged along a perimeter of the light transmissive panel, a plurality of optical components arranged along the perimeter of the light transmissive panel, wherein the light emitters are arranged to emit a respective beam of emitted light and the optical components are configured to direct the emitted light to a path across the light transmissive panel. Optionally, optical components comprise a light guide arranged to receive light from the light emitters through a first surface and couple out light travelling in the light guide to the touch surface through a second surface. The second surface may be diffusively transmissive. The light guide may further comprise a reflective surface configured to internally reflect light travelling in the light guide from the first surface to the diffusive surface.

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4 alkenyl; and halogenated C1-4 alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4 alkyl; C2-4 alkenyl; and halogenated C1-4 alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4 alkyl; C2-4 alkenyl; and halogenated C1-4 alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.

Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.

Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.

Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.

Abstract: A touch sensing apparatus is provided comprising: a light transmissive panel that defines a touch surface, a plurality of light emitters and detectors arranged along a perimeter of the light transmissive panel, a plurality of optical components arranged along the perimeter of the light transmissive panel, wherein the light emitters are arranged to emit a respective beam of emitted light and the optical components are configured to direct the emitted light to a path across the light transmissive panel. Optionally, optical components comprise a light guide arranged to receive light from the light emitters through a first surface and couple out light travelling in the light guide to the touch surface through a second surface. The second surface may be diffusively transmissive. The light guide may further comprise a reflective surface configured to internally reflect light travelling in the light guide from the first surface to the diffusive surface.

Abstract: A touch sensing apparatus is disclosed comprising a panel that defines a touch surface, a plurality of emitters and detectors arranged along a perimeter of the light transmissive panel, and a light directing arrangement arranged adjacent the perimeter. The emitters are arranged to emit a respective beam of emitted light and the light directing arrangement is arranged to direct the light along a light path from the emitters to the touch surface. A diffusive light scattering element is arranged in the light path.

Abstract: A touch sensing apparatus is provided comprising: a light transmissive panel that defines a touch surface, a plurality of light emitters and detectors arranged along a perimeter of the light transmissive panel, a plurality of optical components arranged along the perimeter of the light transmissive panel, wherein the light emitters are arranged to emit a respective beam of emitted light and the optical components are configured to direct the emitted light to a path across the light transmissive panel. Optionally, optical components comprise a light guide arranged to receive light from the light emitters through a first surface and couple out light travelling in the light guide to the touch surface through a second surface. The second surface may be diffusively transmissive. The light guide may further comprise a reflective surface configured to internally reflect light travelling in the light guide from the first surface to the diffusive surface.

Abstract: A touch sensing apparatus is disclosed comprising a panel that defines a touch surface, a plurality of emitters and detectors arranged along a perimeter of the light transmissive panel, and a light directing arrangement arranged adjacent the perimeter. The emitters are arranged to emit a respective beam of emitted light and the light directing arrangement is arranged to direct the light along a light path from the emitters to the touch surface. A diffusive light scattering element is arranged in the light path.

Abstract: A touch sensing apparatus is provided comprising: a light transmissive panel that defines a touch surface, a plurality of light emitters and detectors arranged along a perimeter of the light transmissive panel, a plurality of optical components arranged along the perimeter of the light transmissive panel, wherein the light emitters are arranged to emit a respective beam of emitted light and the optical components are configured to direct the emitted light to a path across the light transmissive panel. Optionally, optical components comprise a light guide arranged to receive light from the light emitters through a first surface and couple out light travelling in the light guide to the touch surface through a second surface. The second surface may be diffusively transmissive. The light guide may further comprise a reflective surface configured to internally reflect light travelling in the light guide from the first surface to the diffusive surface.

Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.

Abstract: Described are methods of prepraing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly usefull for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: An electrosurgical forceps instrument in which an energy conveying structure for efficiently transferring electromagnetic energy (e.g. microwave energy and/or radiofrequency energy) from a coaxial cable to electrodes on the forceps jaws is incorporated into a compact jaw opening structure. The jaw opening structure may be dimensioned to be suitable for insertion down the instrument channel of a endoscope or other scoping device. Alternatively, the device may be configured as a laparoscopic device or be used in open procedures. The instrument may be used as a tool to perform new minimally invasive surgical techniques such as Natural Orifice Transluminal Endosurgery (NOTES) or the like.

Abstract: A touch sensing apparatus is provided comprising: a light transmissive panel that defines a touch surface, a plurality of light emitters and detectors arranged along a perimeter of the light transmissive panel, a plurality of optical components arranged along the perimeter of the light transmissive panel, wherein the light emitters are arranged to emit a respective beam of emitted light and the optical components are configured to direct the emitted light to a path across the light transmissive panel. Optionally, optical components comprise a light guide arranged to receive light from the light emitters through a first surface and couple out light travelling in the light guide to the touch surface through a second surface. The second surface may be diffusively transmissive. The light guide may further comprise a reflective surface configured to internally reflect light travelling in the light guide from the first surface to the diffusive surface.

Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.

Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.